文献速递浆细胞疾病

埃纳妥单抗对生活质量的影响:MagnetisMM-3研究的患者报告结局

Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
PubMed 文献 · Br J Haematol · 2024-02-29

该分析评估MagnetisMM-3研究中接受埃纳妥单抗治疗的复发或难治性多发性骨髓瘤患者的患者报告结局,其中BCMA未暴露者123例、BCMA暴露者64例。患者先接受12 mg(第1天)和32 mg(第4天)两步递增剂量,后于第8天开始76 mg全剂量(每周期28天)。结果显示患者报告结局早期改善,疼痛和疾病症状明显减轻,且不论既往是否接受BCMA靶向治疗均维持或改善症状与总体健康状况。

要点

  • 埃纳妥单抗治疗后患者报告结局早期改善,疼痛和疾病症状明显减轻。
  • 第1周期第15天时,40.2%的BCMA未暴露者和52.6%的BCMA暴露者认为疾病「稍好」或「好很多」。
  • 不论既往是否接受BCMA靶向治疗,埃纳妥单抗均维持或改善症状与总体健康状况。

核心结论

  • 埃纳妥单抗在临床获益之外,可能维持或改善经重度治疗的复发或难治性多发性骨髓瘤患者的生活质量。

研究设计与样本

  • 分析MagnetisMM-3研究(NCT04649359)中BCMA未暴露(n=123)和BCMA暴露(n=64)的复发或难治性多发性骨髓瘤患者的患者报告结局。
  • 患者接受埃纳妥单抗两步递增剂量(第1天12 mg,第4天32 mg),第8天开始76 mg全剂量,每周期28天。
  • 使用经验证的多发性骨髓瘤特异性问卷电子采集总体健康状况、功能和症状数据。

主要发现

  • 患者报告结局早期改善,疼痛和疾病症状明显减轻,患者对未来健康的看法显著改善。
  • 第1周期第15天时,40.2%的BCMA未暴露患者和52.6%的BCMA暴露患者认为疾病「稍好」或「好很多」。
  • 不论既往是否接受BCMA靶向治疗,埃纳妥单抗均维持或改善症状学和总体健康状况。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The physical and emotional burden of relapsed or refractory multiple myeloma (RRMM) has been strongly correlated with declining health-related quality of life (QOL) in the patients it affects. This analysis evaluated patient-reported outcomes (PROs) from B-cell maturation antigen (BCMA)-naive (n = 123) and -exposed (n = 64) patients with RRMM enrolled in the MagnetisMM-3 study (NCT04649359) and treated with the humanized, bispecific BCMA-CD3 antibody elranatamab. Patients received two step-up doses of elranatamab (12 mg on day 1, 32 mg on day 4) before starting the full dose of 76 mg on day 8 (each cycle = 28 days). Global health status, functioning and symptom data were collected electronically using validated and myeloma-specific questionnaires. Improvements in PROs occurred early, with marked reductions in pain and disease symptoms and notable improvements in patients' outlook for their future health. Additionally, 40.2% of BCMA-naive and 52.6% of BCMA-exposed patients perceived their disease as 'a little better' or 'much better' by Cycle 1, Day 15. The results from this analysis demonstrated that elranatamab maintained or improved symptomology and general health status, regardless of prior BCMA-directed therapy. Thus, in addition to its clinical benefits, elranatamab therapy may sustain or improve QOL in heavily pretreated patients with RRMM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mohty M, Bahlis NJ, Nooka AK, et al. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. Br J Haematol. 2024. PMID: 38420657. doi:10.1111/bjh.19346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。